Antibody Engineering2023-11-22T15:13:00-05:00

Antibody Engineering.

Informed Engineering with De Novo Antibody Sequencing and Proteomics.

Antibody engineering is rarely a straightforward journey; it can be viewed as a cyclical process of understanding, design, production, and observation. These stages form the foundation of an informed engineering process, accelerating the development of antibodies for diverse applications.

Gaining a deeper understanding of the starting material, including complete antibody sequences, binding kinetics, binding epitopes and 3D conformations offers essential details to fuel the engineering process.

An informed engineering process requires in-depth characterization on the performance of the resulting engineered antibody. Does the antibody bind to the intended epitope? What are the binding kinetics of the antibody? Was there a change in the glycan profile? How well was it produced? Addressing these questions ensures the effectiveness of engineered antibodies, enhancing their utility in therapeutic and diagnostic applications.

De novo antibody sequencing, epitope mapping with HDX-MS and kinetic analysis with SPR, and glycan analysis can answer these questions to better inform your antibody engineering process.

Services for Antibody Engineering.

We support the antibody engineering efforts of life science companies in all stages of development. Contact Us to discover how we can help with your antibody engineering application.

Antibody Sequencing & Discovery Services.

de novo mAb Sequencing

Obtain amino acid sequences of functional antibodies to facilitate in silico design, rational engineering, humanization, chimerization, affinity maturation, conjugation design and construction of fragments and multi-specifics.
Explore REmAb

Glycan Analysis

Obtain the glycan profile of mAbs, enabling the identification and quantification of key glycans, and ensuring the reproducibility of glycosylation patterns during recombinant antibody expression.
Explore REpAb

Validate Engineered mAb Constructs

Confirm protein sequences and pinpoint the occurrences of any modifications, mispairings, or mutations after protein expression or during cell line development. Minimize troubleshooting efforts with real-time peptide mapping.
Explore MATCHmAb

Binding Kinetics

Test, assess, and evaluate mAb binding kinetic properties (ie. specificity, affinity, efficiency) to evaluate and reevaluate engineering strategies.
Explore SPR Analysis

Epitope Mapping

Characterize antigenic epitopes for the rational design of mAbs, scFvs, and multi-specifics. Determine antibody binding sites on target antigens for FDA and EMEA regulatory filings and IP protection.
Explore HDX-MS

Recombinant Expression

Obtain the amino acid sequence of mAbs and proceed directly to recombinant antibody expression, facilitating a streamlined workflow for further engineering and ensuring a secure and consistent product supply.
Explore Antibody Expression

Application Publications.

CAR-iNKT Cells Targeting Clonal TCRVβ Chains as a Precise Strategy to Treat T Cell Lymphoma

Tags: , , , , , , , , , |

With 22 functional T cell receptor (TCR)Vβ subunit families making up the normal T cell repertoire, signals from these cell surface receptors often determine the fate of normal cells. However, mutations in TCR signaling proteins are frequently associated with peripheral T cell lymphomas (TCLs), including adult T cell leukemia/lymphoma (ATL), which indicates a driving role for TCRs in TCL oncogenesis. As TCL and ATL are clonal in nature, tumour cells typically express a single TCRVβ subunit with no bias in the usage of TCRVβ subunit families. Consequently, targeting the specific TCRVβ subunit presents a promising therapeutic approach that is highly selective and tumour-specific.

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.